FDA Greenlights First-ever Treatment for Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. has received FDA approval for XDEMVY™ (lotilaner ophthalmic solution) 0.25% as a therapeutic solution for Demodex blepharitis,
Read moreTarsus Pharmaceuticals, Inc. has received FDA approval for XDEMVY™ (lotilaner ophthalmic solution) 0.25% as a therapeutic solution for Demodex blepharitis,
Read moreMaintaining traceability in pharmaceutical manufacturing processes is of utmost importance in navigating the intricate landscape of government regulations that influence
Read moreKrystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreAstellas Pharma Inc announced that the US Food and Drug Administration (FDA) has given approval for the oral drug VEOZAHTM
Read moreIn today’s strictly regulated pharmaceutical industry, the need for temperature monitoring solutions is paramount. The quality, reliability, and durability of
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreJanssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read moreJapanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb announced on Friday that the European Commission (EC) has awarded the company with
Read more